Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Market Closed 01-16 16:00:00 EST

70.00

+0.93

+1.35%

盘后68.64

-1.36-1.94%

17:51 EST

High72.01	Low67.62	Vol301.55K
Open68.81	D1 Closing69.07	Amplitude6.36%
Mkt Cap467.78M	Tradable Cap345.21M	Total Shares6.68M
T/O20.99M	T/O Rate6.11%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":70,"timestamp":1768597200000,"preClose":69.07,"halted":0,"volume":301552,"hourTrading":{"tag":"盘后","latestPrice":68.64,"preClose":70,"latestTime":"17:51 EST","volume":2313,"amount":161538.72,"timestamp":1768603919730},"delay":0,"floatShares":4931541,"shares":6682584,"eps":-2.989461,"marketStatus":"Market Closed","change":0.93,"latestTime":"01-16 16:00:00 EST","open":68.81,"high":72.01,"low":67.62,"amount":20994113.56592,"amplitude":0.063559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.989461,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":69.07,"preHourTrading":{"tag":"盘前","latestPrice":67,"preClose":69.07,"latestTime":"08:04 EST","volume":448,"amount":30026.85952,"timestamp":1768568685250},"postHourTrading":{"tag":"盘后","latestPrice":68.64,"preClose":70,"latestTime":"17:51 EST","volume":2313,"amount":161538.72,"timestamp":1768603919730},"volumeRatio":0.9831507569671594},"requestUrl":"/m/hq/s/MNPR","defaultTab":"news","newsList":[{"id":"2603169700","title":"BTIG Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603169700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603169700?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:07","pubTimestamp":1768388831,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jeet Mukherjee from BTIG maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $104.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-monopar-therapeutics-inc-mnpr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-monopar-therapeutics-inc-mnpr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2603694088","title":"Monopar Therapeutics Price Target Maintained With a $104.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2603694088","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603694088?lang=en_us&edition=fundamental","pubTime":"2026-01-14 18:15","pubTimestamp":1768385700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 05:15 ET (10:15 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2603916476","title":"Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Nuvalent (NUVL) and Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603916476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603916476?lang=en_us&edition=fundamental","pubTime":"2026-01-14 17:30","pubTimestamp":1768383030,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acadia Healthcare (ACHC – Research Report), Nuvalent (NUVL – Rese...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-nuvalent-nuvl-and-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-nuvalent-nuvl-and-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACHC","BK4585","MNPR","BK4588","BK4581","NUVL","BK4139","XBI","XLV","BK4539","LABU","BK4185"],"gpt_icon":0},{"id":"2602737666","title":"Monopar Therapeutics Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2602737666","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602737666?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:13","pubTimestamp":1767964380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 08:13 ET (13:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2602373911","title":"Morgan Stanley Initiates Coverage on Monopar Therapeutics With Overweight Rating, $115 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373911","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373911?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:24","pubTimestamp":1767961448,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc (MNPR) has an average rating of Buy and mean price target of $112, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR"],"gpt_icon":0},{"id":"2602321065","title":"Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321065?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:55","pubTimestamp":1767952542,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc (MNPR) has received a new Buy rating, initiated by Morgan Stanley analyst, Maxwell Skor. Maxwell Skor has given his Buy ra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/monopar-therapeutics-alxn1840s-differentiated-efficacy-de‑risked-profile-and-strong-cash-runway-underpin-overweight-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/monopar-therapeutics-alxn1840s-differentiated-efficacy-de‑risked-profile-and-strong-cash-runway-underpin-overweight-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2602326805","title":"JonesTrading Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602326805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602326805?lang=en_us&edition=fundamental","pubTime":"2026-01-09 16:45","pubTimestamp":1767948321,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2600708537","title":"The Year-End 2025 Biotech Rally And What It Means For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600708537?lang=en_us&edition=fundamental","pubTime":"2025-12-31 23:54","pubTimestamp":1767196440,"startTime":"0","endTime":"0","summary":"Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?The performance metrics speak volumes. The iShares Biotechnology ETF  has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF  has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s  Myqorzo for a heart condition, marking the company’s first approval after 27 years ","market":"sh","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IONS","MRK","IE00BBT3K403.USD","IE0005OL40V9.USD","EYPT","QID","QLD","CYTK","LU2089984988.USD","VRNA","NVIW.SI","SQQQ","SG9999014880.SGD","BK4505","SG9999014906.USD",".IXIC","IE00BJT1NW94.SGD","TQQQ","PSQ","LU1116320737.USD","OMER","MNPR","ITCI","LU2430703178.SGD","JNJ","USAW.SI","LU0306807586.USD","USJW.SI","LU1037948897.HKD","GPCR","MNQmain","LU0471298694.HKD","TSYW.SI","LU0256863811.USD","LU1935042991.SGD","LU0432979614.USD","BK4532","IE00B1BXHZ80.USD","IBB","NVS","RNA","IE00BVYPNW00.USD","LU2592432038.USD","BK4581","NQmain","LU0823434740.USD","LU2063271972.USD","PFE"],"gpt_icon":1},{"id":"2595734945","title":"Monopar Therapeutics CFO Quan Anh Vu Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595734945","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595734945?lang=en_us&edition=fundamental","pubTime":"2025-12-30 01:16","pubTimestamp":1767028571,"startTime":"0","endTime":"0","summary":"Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLbHxX9S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Monopar Therapeutics CFO Quan Anh Vu Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"gpt_icon":0},{"id":"2593120905","title":"Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2593120905","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593120905?lang=en_us&edition=fundamental","pubTime":"2025-12-21 21:29","pubTimestamp":1766323797,"startTime":"0","endTime":"0","summary":"We'd be surprised if Monopar Therapeutics Inc. ( NASDAQ:MNPR ) shareholders haven't noticed that the Independent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/independent-director-arthur-klausner-sold-a-bunch-of-shares","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/independent-director-arthur-klausner-sold-a-bunch-of-shares","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MNPR"],"gpt_icon":0},{"id":"1132483281","title":"Stock Track | Monopar Therapeutics Soars 8.74% on Bullish Analyst Rating and $130 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1132483281","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132483281?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:02","pubTimestamp":1763492541,"startTime":"0","endTime":"0","summary":"Shares of Monopar Therapeutics (MNPR) surged 8.74% during intraday trading on Tuesday, following a bullish report from JonesTrading analyst Soumit Roy. The analyst maintained a \"Buy\" rating on the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNPR"],"gpt_icon":0},{"id":"1182700154","title":"Stock Track | Monopar Therapeutics Soars 8.74% Following Analyst's Buy Rating and $130 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1182700154","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182700154?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:02","pubTimestamp":1763492536,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) stock surged 8.74% during Tuesday's intraday trading session, following a bullish analyst report. The significant uptick in share price comes as investors react positively...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNPR"],"gpt_icon":0},{"id":"2584495041","title":"Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495041","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584495041?lang=en_us&edition=fundamental","pubTime":"2025-11-19 02:45","pubTimestamp":1763491527,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. Soumi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-monopar-therapeutics-inc-promising-alxn1840-data-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-monopar-therapeutics-inc-promising-alxn1840-data-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2583689591","title":"Monopar Therapeutics Shares Fall After Raymond James Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2583689591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583689591?lang=en_us&edition=fundamental","pubTime":"2025-11-15 03:54","pubTimestamp":1763150091,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics  shares fell 6.8% in recent Friday trading after Raymond James downgraded the stock to outperform from strong buy and cut its price target to $123 from $142.Trading volume stood at about 200,000 shares, compared with the daily average of roughly 88,000.Price: 81.11, Change: -5.90, Percent Change: -6.78","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNPR","RJF"],"gpt_icon":0},{"id":"1121303799","title":"Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1121303799","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121303799?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:33","pubTimestamp":1763130781,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MNPR"],"gpt_icon":0},{"id":"2583356570","title":"BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356570","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356570?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:17","pubTimestamp":1763119023,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jeet Mukherjee from BTIG reiterated a Buy rating on Monopar Therapeutics Inc, with a price target of $104.00. The c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-keeps-their-buy-rating-on-monopar-therapeutics-inc-mnpr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR"],"gpt_icon":0},{"id":"2583512927","title":"Monopar Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512927?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:25","pubTimestamp":1763069100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 16:25 ET (21:25 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2583598307","title":"Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598307","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598307?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:06","pubTimestamp":1763039201,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses of $(0.37) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48831407/monopar-therapeutics-q3-eps-0-48-misses-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"gpt_icon":0},{"id":"2583459885","title":"Monopar Therapeutics reports third quarter net loss of $3.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583459885","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583459885?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:01","pubTimestamp":1763038896,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. reported a net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025, compared to a net loss of $1.3 million, or $0.37 per share, for the same period in 2024. As of September 30, 2025, the company held $143.7 million in cash, cash equivalents, and investments. Recent business developments include FDA clearance of an IND application for MNPR-101-Lu, a Phase 1 trial for advanced or metastatic solid tumors, and preparations to submit a New Drug Application for ALXN1840 for Wilson disease in early 2026. The company also completed a share repurchase of 550,229 shares from Tactic Pharma for $35 million, following a public offering, resulting in net proceeds of approximately $91.9 million before expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL1tBGxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","MNPR","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2583356005","title":"Press Release: Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356005","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356005?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038800,"startTime":"0","endTime":"0","summary":"WILMETTE, Ill., Nov. 13, 2025  -- Monopar Therapeutics Inc.  , a clinical--stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments.On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840  at the 150th American Neurological Association  Annual Meeting. Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan delivered the poster and oral presentations. The new findings presented at ANA highlight the long-term neurological benefit of ALXN1840, and follow the European Association for the Study of the Liver  International Liver Congress presentation in May on the long-term hepatic and systemic safety and efficacy data. Together, these findings underscore the potential of ALXN1840 to favorably impact both neurological and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","BK4022","R","MNPR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":0.1111},{"period":"1month","weight":0.034},{"period":"3month","weight":-0.1264},{"period":"6month","weight":0.506},{"period":"1year","weight":1.2966},{"period":"ytd","weight":0.072}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.247166},{"month":2,"riseRate":0.333333,"avgChangeRate":0.12127},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.21291},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.030342},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.085228},{"month":6,"riseRate":0.666667,"avgChangeRate":0.04528},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.047687},{"month":8,"riseRate":0,"avgChangeRate":-0.159034},{"month":9,"riseRate":0.333333,"avgChangeRate":0.484161},{"month":10,"riseRate":0.5,"avgChangeRate":0.223985},{"month":11,"riseRate":0.666667,"avgChangeRate":0.047001},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.031256}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction